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Objective:  Endothelial nitric oxide inhibits smooth muscle cell proliferation, re-
ducing the chance of vascular intimal thickening. In this study we investigated
whether the superior long-term patency of the internal thoracic artery in human
coronary bypass grafting compared with that of the saphenous vein could be
explained by different levels of nitric oxide production.
Methods: The baseline endogenous nitric oxide production appeared to be 50%
higher in the internal thoracic artery than in the saphenous vein. Previously, it was
shown that vascular endothelial growth factor and the vascular endothelial growth
factor receptors KDR (Flk-1) and Flt-1 are expressed in both internal thoracic arter-
ies and saphenous veins and that vascular endothelial growth factor receptor densi-
ty was higher in internal thoracic arteries than in saphenous veins. Therefore, we
also investigated the influence of vascular endothelial growth factor on nitric oxide
release in both the internal thoracic artery and the saphenous vein. 
Results: Vascular endothelial growth factor augmented nitric oxide production by
approximately 50% in the saphenous vein and 100% in the internal thoracic artery.
As shown by means of immunohistochemistry, expression of endothelial constitu-
tive nitric oxide synthase was similar in the internal thoracic artery and the saphe-
nous vein, and no inducible nitric oxide synthase was expressed in any of the vas-
cular segments.
Conclusion: Vascular endothelial growth factor augments endothelial constitutive
nitric oxide synthase–dependent nitric oxide release to a greater extent in the inter-
nal thoracic artery than in the saphenous vein. These findings may help to explain
the long-term superiority of the internal thoracic artery versus the saphenous vein
as a conduit for coronary artery bypass. 
Intimal thickening is an important cause of late coronary vein graft occlusion.The internal thoracic artery (ITA) has been shown to have a much better long-term patency as a conduit for coronary artery bypass than the saphenous vein(SV).1 Because nitric oxide (NO) has been reported to reduce vascularsmooth muscle cell mitogenesis,2 a process known to contribute to intimalthickening, it is conceivable that a difference in baseline and vascular
endothelial growth factor (VEGF)–stimulated NO production between arteries and
veins is responsible for the difference in patency rates between these vessels.
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Previously, we showed that in rabbits the baseline produc-
tion of NO was significantly higher in segments of arteries
than in segments of veins.3 This baseline NO production was
found to be endothelium derived and dependent on endothelial
constitutive NO synthase (ecNOS). In addition, we found that,
at least in rabbits, VEGF augments NO release more in arter-
ies than in veins. VEGF is a 45-kd heparin-binding dimeric
glycoprotein that has been reported to induce mitogenesis in
endothelial cells but not in other cell types.4 Because of the
unique aspect of its narrow target specificity, VEGF plays a
crucial role in endothelial cell differentiation and is obligatory
for normal development of the vasculature in mammalian
embryos.5,6 The presence of VEGF protein and the expression
of both VEGF receptors, KDR (Flk-1) and Flt-1, in normal
segments of human ITAs and SVs7 also suggest a biologic
function of this growth factor in the maintenance and repair of
the luminal endothelium in human subjects.
In the present study we investigated the basal NO release
from freshly isolated segments of human ITAs and SVs by
using the Griess method.3 In addition, we studied to what
extent VEGF influences NO production in these vascular
segments. Differences in VEGF-mediated NO production
between arteries and veins, if any, may be caused by higher
VEGF receptor expression (Flk-1/KDR and Flt-1)7 or a
higher expression of ecNOS or inducible (iNOS) NOS pro-
tein in ITAs than in SVs. Therefore, in both types of human
vessels, we also assessed the expression of ecNOS and
iNOS protein by means of immunohistochemistry.
Figure 1. Effect of VEGF (10 µg/mL) on NO release from the human ITA and SV. The involvement of NOS was stud-
ied by adding the active substrate L-arginine or by adding NG-monomethyl-L-arginine (L-NMMA), which is an
inhibitor of NO synthesis. Involvement of the endothelium and Ca2+ was studied as well. L-Arginine (0.2 mol/L) was
added at –15 minutes to ITA (B) and SV (D); other substances were added at 0 minutes. n, Number of vascular seg-
ments; [NO], NO concentration; SA, surface area; no endothelium, endothelium-denuded vascular segments; no
calcium, CaCl2-free organ bath solution. All concentrations represent final bath concentrations. *P < .05 (A)  SV:
VEGF versus SV: no VEGF, (B) ITA: L-arginine versus ITA: no VEGF, (C) ITA: VEGF versus all other curves and (D) SV:
VEGF/L-arginine versus all other curves. †P < .05 (A) ITA: VEGF versus ITA: no VEGF. #P < .05 (B) ITA: VEGF/N G-
monomethyl-L-arginine versus ITA: no VEGF at t = 12 minutes, (D) SV: VEGF/NG-monomethyl-L-arginine versus SV:
no VEGF at t = 12 minutes.
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Methods
Patients and Vessel Preparation
Experiments were performed on vessels isolated from 32 patients
(23 male and 9 female patients). All women were postmenopausal.
All patients underwent coronary artery bypass grafting. Informed
consent was obtained for the ex vivo use of blood vessel speci-
mens. The study was approved by the ethical committees on clini-
cal research of the University Hospital Maastricht. The vessel
specimens were prepared as described previously.3
Vascular segments from 15 patients were used for measurement of
NO production. Some segments were fixed in buffered 4% formalin
solution for at least 24 hours, dehydrated, embedded in paraffin, and
stored for immunohistochemistry.
Measurement of NO
Vascular segments were distributed over 2 organ chambers.
Concentrated test substances were administered to one of the cham-
bers (t = 0), and the other chamber served as a control to obtain base-
line NO values. NO was determined at different points in time before
and after administration of the reagents to be tested by means of spec-
trophotometric assessment of the nitrite/nitrate content.
Histology, Immunohistochemistry, and Morphometry
To investigate the presence and localization of ecNOS and
iNOS, we used paraffin-embedded segments of ITAs and SVs.
Samples from normal human colon and from colon affected by
active colitis ulcerosa (active lesions) were used as positive con-
trols for ecNOS8 and iNOS,9 respectively. Slides were overlaid
with mouse monoclonal anti-human ecNOS or iNOS antibodies
(Santa Cruz Biotechnology, Santa Ana, Calif). Both antibodies
have been shown to be specific for the tested proteins. For a neg-
ative control, the primary antibody was omitted. The tissue was
counterstained with hematoxylin and coverslipped. To specifi-
cally estimate which fraction of luminal endothelial cells posi-
tively stained for ecNOS or iNOS, parallel sections were incu-
bated with the endothelial-specific anti-Ulex europeus lectin
peroxidase complex (45 minutes at room temperature, 1:100;
DAKO Corporation, Carpinteria, Calif), as described earlier.10
In 2 parallel sections of each specimen, the endothelial cell cov-
erage of the lumen was determined by means of morphometry.
Average values for endothelial coverage in these selected vascu-
lar samples were as follows: 0.93 ± 0.07 (n = 9) in ITAs and 0.93
± 0.04 in SVs (n = 8).
Statistical Analysis
Values are given as means ± SEM, unless indicated otherwise. If
n = 2, bars indicate the range of obtained values. The data on NO
measurements were evaluated by using a 2-factor (significance
over time and significance of drug effect) analysis of variance for
repeated measurements. For comparison of paired values, a 2-
tailed Student t test was applied. In all experiments n equals the
number of vessels that were used for each experiment.
Figure 2. The expression of endothelial constititutive NOS and iNOS on endothelial cells in human ITAs and SVs.
Mouse monoclonal anti-human endothelial NOS (eNOS) or iNOS protein antibodies were used for immunohisto-
chemistry. The brown color indicates a signal specific for the primary antibody used. A, Positive endothelial NOS
staining on luminal endothelial cells (arrow) of human ITA. B, Positive endothelial NOS staining on luminal endothe-
lial cells (arrow) of human SV. C, Positive endothelial NOS staining on vascular endothelial cells of blood vessels
of different caliber in the stroma of human colon. A-C, Large arrows indicate the endothelium; small arrow indicates
a colon villus. D, No iNOS staining on human ITA. E, No iNOS staining on human SV. F, Positive iNOS staining on stro-
mal cells in a sample from an active lesion of a human colon affected by ulcerative colitis (UC). Arrow indicates a
colon villus. Scale bars represent 100 µg.
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Results
NO Release by Segments of ITA and SV
The baseline production of NO was approximately 50%
higher in ITAs than in SVs (Figure 1, A). After administra-
tion of VEGF, release of NO significantly increased by
about 100% in ITAs and by about 50% in SVs. Both vessel
types displayed a maximal value after 8 minutes, reflecting
the time necessary for downstream signaling after ligation
of the VEGF receptors.3,11 Addition of L-arginine to the
organ bath solution (at t = –15 minutes) resulted in a signifi-
cant approximately 2-fold increase of baseline NO production
in ITAs (Figure 1, B). In SVs addition of L-arginine (at t = –15
minutes) also resulted in a significant increase of baseline NO
production of approximately 1.5-fold, as can be seen in Figure
1, D (t = –3 to t = 0 minutes). Coadministration of the NOS
inhibitor NG-monomethyl-L-arginine totally abrogated the
response to VEGF in both ITAs (Figure 1, B) and SVs (Figure
1, D). In both ITAs (Figure 1, B; t = 12) and SVs (Figure 1, D;
t = 12) NO production decreased to levels significantly lower
than baseline values when NG-monomethyl-L-arginine was
coadministered. Mechanical disruption of the endothelium in
ITAs (Figure 1, C) or removal of Ca2+ from the organ bath
solution in which segments of ITAs (Figure 1, C) or SVs
(Figure 1, D) were bathed also prevented an increase in NO
production after administration of VEGF.
Expression of ecNOS and iNOS in ITAs and SVs 
In all ITA (n = 9) and SV (n = 8) samples, ecNOS+ endothe-
lial cells were observed, indicating proper expression of this
constitutively active enzyme in quiescent endothelium of
both vessel types (Figure 2). In contrast, the iNOS protein
was not expressed in any of the ITA and SV segments.
Discussion
The findings in the present study show that baseline NO
release is approximately 50% higher in human ITAs than in
SVs and that VEGF is capable of inducing a significant
increase in NO release in these vessels through activation of
ecNOS. Administration of VEGF results in an approximate-
ly 100% increase in NO release in ITAs and an approxi-
mately 50% increase in SVs. The higher density of the
VEGF tyrosine kinase receptors KDR (Flk-1) and Flt-1 in
ITAs than in SVs, as shown in a previous study,7 provides a
possible explanation for the higher VEGF-stimulated
release of NO in ITAs compared with SVs. ecNOS seems to
be equally expressed in human ITA and SV endothelium.
iNOS does not seem to play a role in these processes. The
higher NO production at baseline and after VEGF stimula-
tion in ITAs than in SVs may play a role in the superior
long-term patency of the ITA when used as a coronary
artery bypass graft.12
The enhanced release of NO in both ITAs and SVs after
the administration of L-arginine indicates that these vessels
are able to produce more NO when stimulated but does not
explain the difference in baseline NO release between this
artery and this vein. From our study, it may be concluded
that VEGF augments NO production when ligated to its
receptors Flk-1/KDR and Flt-1 on human ITA and SV
endothelial cells. The unique presence of these receptors
on endothelial cells is demonstrated by the finding that
mechanical disruption of the vascular endothelium totally
abrogated the response to VEGF. Both ITA and SV
endothelial cells contain ecNOS. This ecNOS constitutes a
membrane-bound complex with calmodulin, thus being
sensitive to cytosolic calcium fluctuations.13 This complex
is involved in the conversion of L-arginine to citrulline,
yielding NO. When VEGF binds to its tyrosine kinase
receptors, they must dimerize to activate downstream sig-
naling. After dimerization, phospholipase Cγ1 is phospho-
rylated, which causes the release of inositol-triphosphate,
resulting in an increase in cytosolic Ca2+ and a subsequent
increase of ecNOS activity and NO production.11
Consistent with this mechanism is the observation in the
present study that removal of Ca2+ from the organ bath
solution abolishes the increase in NO production after
VEGF administration.
The role of VEGF in adult human blood vessels still needs
to be clarified. VEGF was originally discovered as a result
of its ability to increase permeability of vascular endotheli-
um and to induce endothelial cell mitogenesis; it has been
reported as mandatory in the normal development of the
vasculature of mammalian embryos.6 In the adult, vascular
smooth muscle cells from ITAs and SVs actively secrete
VEGF.7 However, both VEGF receptors, Flk-1/KDR and
Flt-1, appear to be upregulated, predominantly at sites of
recurrent neovessel proliferation and especially in conjunc-
tion with hypoxia14 and ischemia.15
In the present study we have documented that the VEGF
receptors are functional in both arteries and veins, as
demonstrated by the increased NO release after VEGF
administration. Taken together with the notion that VEGF
itself is expressed in adult vascular smooth muscle cells7
and that it may traffic to the adjacent endothelium and lig-
ate endothelial VEGF receptors, this observation suggests
that in healthy, mature vessels the biologic function of this
growth factor is not limited to angiogenesis. VEGF pro-
motes preservation of an intact barrier between circulating
blood, and the vessel wall constitutes a critical condition for
normal vessel behavior. Throughout life, blood vessels are
often exposed to cytokines, proteases, oxidative stress, and
other factors that may damage or impair endothelial func-
tion. Under such circumstances, VEGF-augmented NO pro-
duction may be required for recurrent repair of damaged or
dysfunctional endothelium, thus protecting the vessel from
thrombotic events, leukocyte adhesion, and vasospasm. In
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addition, intact endothelial NO production is mandatory to
inhibit medial smooth muscle cell proliferation.2,16 This fea-
ture is relevant to the preservation of vascular patency as
well because migration of proliferating medial smooth mus-
cle cells has been shown to contribute to the occurrence of
intimal thickening in coronary bypass grafts and native
coronary arteries. Therefore, in mature vessels VEGF could
play a role in the maintenance, repair, or both, of the lumi-
nal endothelium by augmenting NO production.
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